There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xtant Medical Holdings (XTNT – Research Report) and Verrica Pharmaceuticals (VRCA – Research Report) with bullish sentiments.
Xtant Medical Holdings (XTNT)
In a report released today, Chase Knickerbocker from Craig-Hallum reiterated a Buy rating on Xtant Medical Holdings, with a price target of $1.70. The company’s shares closed last Wednesday at $0.79.
According to TipRanks.com, Knickerbocker is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Xtant Medical Holdings with a $2.35 average price target, implying a 201.3% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $3.00 price target.
See the top stocks recommended by analysts >>
Verrica Pharmaceuticals (VRCA)
In a report released today, Serge Belanger from Needham maintained a Buy rating on Verrica Pharmaceuticals, with a price target of $16.00. The company’s shares closed last Wednesday at $9.10.
According to TipRanks.com, Belanger is a 3-star analyst with an average return of
Verrica Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $14.20, representing a 49.5% upside. In a report issued on May 13, TD Cowen also maintained a Buy rating on the stock with a $15.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on XTNT:
- Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds
- Xtant Medical’s Earnings at Risk: The Unhedged Perils of Currency Fluctuations
- Xtant Medical sees FY24 revenue $112M-$116M
- Xtant Medical reports Q4 EPS (3c) vs (2c) last year
- Xtant Medical to Issue Fourth Quarter and Full Year 2023 Financial Results on April 1, 2024
